ALK and neuroblastoma: The selective differences in TNO155 sensitivity that we observed between ALK mutated and nonmutated neuroblastoma cells resemble those reported for ALK-TKI treatments (13); however, our results reveal no substantial differences based on specific ALK missense mutations.